Nasdaq:KALV
KalVista Pharmaceuticals, Inc.
A clinical-stage biotech firm targeting rare diseases and oncology with strong cash reserves but no current commercial revenue.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe in the high-risk, high-reward potential of KalVista's rare disease pipeline and expect successful Phase 2 or 3 trial readouts that could trigger substantial value creation. The strong liquidity position of $132.3M provides ample runway to advance multiple programs without immediate need for dilutive fundraising.
Bear Case
The stock is unattractive due to a massive operating loss of $183.4M, zero revenue generation, and a retained earnings deficit exceeding $650M which signals deep structural challenges. With cash flow from operations at -$152.9M and no commercial sales, the company relies entirely on external capital markets to survive.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for rare diseases and oncology, primarily operating within the United States. The company leverages its proprietary platform to advance investigational drugs through preclinical and clinical development stages without current commercial revenue streams. Key financial highlights include a significant cash position of $132.3M as of the latest period and substantial investment in research and development totaling $71.7M annually.
Analysis
Management Discussion
Management has maintained a healthy cash balance of $132.3M while operating at a net loss of $183.4M, driven by heavy investments in research and development of $71.7M and general administrative costs of $116.3M. The significant net change in cash of $100.5M was largely fueled by financing activities rather than operations, indicating the company is still in a capital-intensive growth phase typical for clinical-stage biotechs.
Industry Overview
The rare disease and oncology biotechnology sector is characterized by high failure rates in clinical trials but offers significant market exclusivity periods for approved therapies. Companies in this space typically require substantial upfront R&D investment before achieving any commercial milestone or generating positive cash flow.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $110.9M | $140.4M | $188.0M |
| Operating Income | $-110.9M | $-140.4M | $-188.0M |
| R&D | $80.3M | $86.2M | $71.7M |
| G&A | $30.6M | $54.3M | $116.3M |
| Stock-Based Comp | $9.9M | $21.9M | $12.3M |
| D&A | $718.0K | $816.0K | $941.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $18.0M | $13.8M | $7.9M |
| Interest Income | $2.2M | $3.9M | $6.4M |
| Pre-Tax Income | $-92.9M | $-126.6M | $-180.1M |
| Income Tax | $0 | $0 | $3.4M |
| Continuing Ops | $-92.9M | $-126.6M | $-183.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-92.9M | $-126.6M | $-183.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-92.9M | $-126.6M | $-183.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $172.3M | $225.7M | $241.7M |
| Cash & Equivalents | $56.2M | $31.8M | $131.6M |
| Prepaid Expenses | $6.4M | $6.8M | $19.7M |
| Other Current Assets | $109.7M | $187.1M | $90.4M |
| Long-Term Assets | $10.9M | $9.7M | $9.1M |
| PP&E (Net) | $2.9M | $2.2M | $2.0M |
| Operating Leases | $7.8M | $6.9M | $5.5M |
| Other LT Assets | $106.0K | $567.0K | $1.5M |
| Total Assets | $183.2M | $235.4M | $250.8M |
| Current Liabilities | $15.0M | $22.8M | $45.2M |
| Accounts Payable | $4.8M | $9.1M | $4.9M |
| Current Leases | $1.1M | $1.3M | $2.0M |
| Deferred Revenue | — | — | $11.0M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $7.1M | $6.0M | $110.2M |
| LT Operating Leases | $7.1M | $6.0M | $4.3M |
| Other LT Liab | $0 | $0 | $105.9M |
| Total Liabilities | $22.2M | $28.8M | $155.4M |
| Shareholders' Equity | $161.0M | $206.6M | $95.4M |
| Retained Earnings | $-343.1M | $-469.7M | $-653.2M |
| AOCI | $-3.1M | $-3.5M | $-5.2M |
| Total L&E | $183.2M | $235.4M | $250.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-92.9M | $-126.6M | $-183.4M |
| Non-Cash Adjustments | $21.3M | $29.3M | $-1.7M |
| Working Capital Changes | $-3.7M | $8.1M | $32.2M |
| Cash from Operations | $-75.3M | $-89.2M | $-152.9M |
| Capital Expenditures | $1.2M | $42.0K | $434.0K |
| Cash from Investing | $41.4M | $-84.7M | $91.0M |
| Cash from Financing | $58.1M | $150.7M | $159.7M |
| FX Effect | $1.2M | $-1.2M | $2.6M |
| Net Change in Cash | $25.5M | $-24.4M | $100.5M |
| Beginning Cash | $30.7M | $56.2M | $31.8M |
| Ending Cash | $56.2M | $31.8M | $132.3M |
Frequently Asked Questions
How does KalVista Pharmaceuticals, Inc. make money?
The company operates primarily through a single business segment focused on proprietary drug discovery and development for rare disease indications and oncology, utilizing internal research teams to advance compounds from preclinical to clinical trial phases.
What are the main risks for KALV?
The company faces high risk of total loss of value due to lack of commercial revenue and reliance on successful drug approvals, potential dilution from common share issuances totaling $55.9M in the latest period, regulatory hurdles in bringing rare disease therapies to market, and intense competition from established pharma giants.
What is KALV's competitive advantage?
KalVista possesses a specialized technology platform targeting specific biological pathways in rare diseases, maintaining a robust cash runway of over three years based on current burn rates, and leveraging strategic partnerships or grants implied by the significant financing cash flows.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.